Vol. 2 No. 6 (2022): June
Reimbursement Reviews

Alpha1-Proteinase Inhibitor (Human) (Zemaira)

Published June 14, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses alpha1-proteinase inhibitor (human) (Zemaira), 60 mg/kg body weight administered by IV infusion once weekly.
  • Indication: Maintenance treatment of adults with severe alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema.